Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Moataz B. Zewail"'
Publikováno v:
Journal of Drug Delivery Science and Technology. 79:104040
Autor:
Hussein M. El-Husseiny, Eman A. Mady, Walaa A. El-Dakroury, Moataz B. Zewail, Mina Noshy, Amr M. Abdelfatah, Ahmed S. Doghish
Publikováno v:
Applied Materials Today. 29:101560
Autor:
Moataz B. Zewail, Gihan F.Asaad, Salma M. Swellam, Sama M. Abd-allah, Sahar K.Hosny, Salma K. Sallah, Jehan E.Eissa, Salma S.Mohamed, Walaa A. El-Dakroury
Publikováno v:
International Journal of Pharmaceutics. 624:122006
Lornoxicam (LRX) is a potent nonsteroidal anti-inflammatory drug (NSAID) used extensively to manage pain and inflammatory conditions. However, the drug possesses poor aqueous solubility (i.e., BCS class II) and a short half-life (3-4 h). Mucoadhesive
Publikováno v:
International Journal of Clinical Practice
Background Globally, antibiotics misuse by the public has been reported in the era of COVID-19, despite the discouraging instructions of the World Health Organization, especially for mild cases. Objective Is to describe this antibiotic misuse and its
Publikováno v:
International Journal of Pharmaceutics. 611:121303
Famotidine (FMD) is a highly potent H2-receptor antagonist used in peptic ulcer treatment. However, the drug possesses poor aqueous solubility and permeability. FMD-loaded solid self-nanoemulsifying drug delivery system (FMD-S-SNEDDS) comprised of La
Publikováno v:
Journal of Drug Delivery Science and Technology. 61:102320
A fixed-dose combination of Candesartan cilexetil (CAN) and Hydrochlorothiazide (HCTZ) is commonly used for the management of hypertension. CAN (BCS class II) and HCTZ (BCS class IV) suffer from inadequate oral bioavailability. Herein, the study aims